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ABSTRACT
Background: Dissemination bias in clinical research
severely impedes informed decision-making not only
for healthcare professionals and patients, but also for
funders, research ethics committees, regulatory bodies
and other stakeholder groups that make health-related
decisions. Decisions based on incomplete and biased
evidence cannot only harm people, but may also have
huge financial implications by wasting resources on
ineffective or harmful diagnostic and therapeutic
measures, and unnecessary research. Owing to
involvement of multiple stakeholders, it remains easy
for any single group to assign responsibility for
resolving the problem to others.
Objective: To develop evidence-informed general and
targeted recommendations addressing the various
stakeholders involved in knowledge generation and
dissemination to help overcome the problem of
dissemination bias on the basis of previously collated
evidence.
Methods: Based on findings from systematic reviews,
document analyses and surveys, we developed general
and targeted draft recommendations. During a 2-day
workshop in summer 2013, these draft
recommendations were discussed with external experts
and key stakeholders, and refined following a rigorous
and transparent methodological approach.
Results: Four general, overarching recommendations
applicable to all or most stakeholder groups were
formulated, addressing (1) awareness raising, (2)
implementation of targeted recommendations, (3) trial
registration and results posting, and (4) systematic
approaches to evidence synthesis. These general
recommendations are complemented and specified by
47 targeted recommendations tailored towards funding
agencies, pharmaceutical and device companies,
research institutions, researchers (systematic reviewers
and trialists), research ethics committees, trial
registries, journal editors and publishers, regulatory
agencies, benefit (health technology) assessment
institutions and legislators.
Conclusions: Despite various recent examples of
dissemination bias and several initiatives to reduce it,
the problem of dissemination bias has not been
resolved. Tailored recommendations based on a
comprehensive approach will hopefully help increase
transparency in biomedical research by overcoming the
failure to disseminate negative findings.
INTRODUCTION
In order to make informed decisions, health-
care practitioners, consumers, public health
professionals, policymakers, and health and
research funding bodies rely on evidence
from clinical research. The generation of evi-
dence is made possible because patients
Strengths and limitations of this study
▪ Comprehensive set of evidence-informed recom-
mendations aimed at reducing dissemination
bias based on work conducted as part of
European Union FP7 project (Overcome failure to
Publish nEgative fiNdings (OPEN) project; http://
www.open-project.eu).
▪ General and specific recommendations, both tar-
geted at various key stakeholder groups involved in
the knowledge generation and translation process.
▪ Use of a rigorous and transparent methodology
to develop recommendations including at con-
sensus meeting including external experts and
stakeholders.
▪ Iteration of some recommendations that are not
new but have so far not been broadly implemented.
Meerpohl JJ, et al. BMJ Open 2015;5:e006666. doi:10.1136/bmjopen-2014-006666 1
Open Access Research
participate in clinical trials, and accept any research-
related risks and burdens. To inform medical decision-
making, demonstrate respect to trial participants and
maintain public trust in clinical research, it is important
that such evidence is made available in an easily access-
ible and unbiased way.1 However, many research ﬁndings
are either not published at all (an estimated 50%),2 or
only selectively, that is, with a bias towards speciﬁc
aspects or presenting only partial information.
Healthcare professionals and policymakers are therefore
frequently unable to make decisions based on the entire
relevant research evidence.3 This problem has been
called ‘publication bias’,4 or—as more recently sug-
gested—‘dissemination bias’, to reﬂect the multiple
facets of this problem.5 6 Dissemination bias has recently
received attention due to initiatives such as the AllTrials
campaign (http://www.alltrials.net7) and the RIAT pro-
posal,8 the discussion of oseltamivir in the context of
avian inﬂuenza,9 and announcements from companies,
for example, GlaxoSmithKline, to grant access to
patient-level data from all company trials.10 However,
general awareness of this problem and, even more
importantly, the necessity to address and resolve it, has
presumably not yet been fully recognised by many
stakeholders.
Therefore, the European Commission called for pro-
jects to investigate the extent and impact of dissemin-
ation bias, and to develop recommendations to
overcome incomplete or selective access to trial results.
The European Union has committed funds to two pro-
jects, Overcome failure to Publish nEgative ﬁNdings
(OPEN; http://www.open-project.eu)11 and UNCOVER
(http://www.ait.ac.at/uncover), supported within the
Seventh Framework Program. The two projects used
different methodologies but aimed to address similar
problems, namely, the non-publication—or in a broader
sense the non-dissemination—of the complete data of
all clinical trials.
We present the results of the 24-month OPEN project
that ran from November 2011 to October 2013. As an
interdisciplinary initiative, it brought together academics
and stakeholders from across Europe, with the aim of
developing evidence-informed recommendations and
strategies for overcoming the failure to publish negative
research ﬁndings.
One activity of OPEN was to conduct a series of system-
atic reviews to assess the occurrence of non-publication of
research ﬁndings and the resulting dissemination bias.
These reviews addressed aspects such as existing termin-
ology to describe problems of publication and related
biases,5 available methods to detect and measure dissem-
ination bias,12 and the extent,13 and impact,14 of the
problem of non-publication of research ﬁndings.
Another focus of OPEN was to describe current prac-
tices by various players involved in knowledge generation
and knowledge translation to provide insights about how
to avoid or reduce bias due to non-publication of
research ﬁndings, and to identify ways to change
practices that contribute to the problem. This has been
addressed by assessing and evaluating the policies and
procedures in place for preventing dissemination bias by
the main parties involved in approving, funding, con-
ducting, publishing, disseminating and assessing clinical
research. Different work packages of OPEN have sur-
veyed representatives of funding agencies, the pharma-
ceutical industry, research ethics committees, research
institutions, researchers,15 trial registers,16 medical jour-
nals,17 regulatory agencies and beneﬁt (health technol-
ogy) assessment agencies such as NICE in the UK
(http://www.nice.org.uk) and IQWiG in Germany
(http://www.iqwig.de).
Findings from the OPEN work packages informed a
2-day recommendations workshop in May 2013, attended
by the OPEN project partners, researchers from the
UNCOVER project and selected key stakeholders from
across the world. The workshop aimed at developing
and reﬁning a set of general and targeted recommenda-
tions designed to speciﬁcally consider the roles that the
respective stakeholder groups should play in reducing
the incomplete dissemination of research ﬁndings.
This article ﬁrst describes the process used to reach a
consensus on the recommendations, followed by a dis-
cussion of the general recommendations, which are
aimed at the major stakeholders in the knowledge trans-
lation process. It then presents 47 concrete recommen-
dations complementing the general recommendations
aimed at the speciﬁc target groups, namely, funding
agencies, pharmaceutical and device companies,
research institutions, researchers (systematic reviewers
and trialists), research ethics committees, trial registries,
journal editors and publishers, regulatory agencies,
beneﬁt assessment institutions, and legislators.
METHODS
Based on the data gathered in each OPEN work
package (ie, conducted surveys, qualitative studies, and
systematic reviews; see online supplementary ﬁgure),
each of these groups formulated 4–7 recommendations
on how to reduce dissemination bias tailored to their
respective key group in the knowledge translation
process. These recommendations were compiled,
ordered, and harmonised to form draft recommenda-
tions used as the basis for discussion at the OPEN work-
shop, including further international key stakeholders in
clinical research. The focus of these recommendations
was on non-dissemination of full trials rather than the
selective reporting of outcomes2 and/or analyses.18 This
workshop was held in Freiburg, Germany, on 23–24 May
2013, in order to reach a consensus and to ﬁnalise the
recommendations. The participants were the members
of the OPEN Consortium (see online supplementary
appendix 1), members of the OPEN advisory board (see
online supplementary appendix 2), and 11 stakeholders
from relevant key groups (see online supplementary
appendix 3). Workshop participants discussed the draft
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recommendations in a structured and transparent
manner, and decided on consistent deﬁnitions to be
used in the phrasing of its recommendations (eg, what
is meant by ‘clinical trial’; see box 1).
The recommendations were also discussed in small
groups. To structure the discussion and to facilitate the
documentation of the judgements underlying the recom-
mendations, a decision table was used for rating each
individual recommendation (ﬁgure 1). The decision
tables required each group to assess ﬁve criteria for each
recommendation, and to grade it as a ‘strong recommen-
dation’ or only a ‘recommendation’, based on their jud-
gements. The following ﬁve explicit criteria, which are
conceptually based on the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
approach for developing recommendations,19 20 were
assessed for each recommendation:
▸ Conﬁdence in effectiveness—whether the group was
conﬁdent that if this recommendation were imple-
mented it would effectively reduce dissemination bias.
▸ Balance of beneﬁts and downsides—whether the
group thought that the beneﬁts of this recommenda-
tion would clearly outweigh its potential downsides.
▸ Likelihood of opposition—whether the group
thought that there would be no or only minor oppos-
ition to the implementation of this recommendation
by relevant key groups.
▸ Resource use—whether the group thought that
implementing this recommendation would require
only limited resources (both direct ﬁnancial costs and
indirect resources).
▸ Implementability and feasibility—whether the group
thought that this recommendation could be easily
implemented (within a reasonable timeframe) and
easily sustained.
For all ﬁve criteria, the groups were asked to provide a
‘yes or no’ answer and an explanation for their judge-
ment. Regarding the classiﬁcation as either ‘strong rec-
ommendation’ or ‘recommendation’, we decided not to
use a strict rule (eg, ≥3 saying yes results in strong rec-
ommendation, <2 saying yes results in recommenda-
tion), but rather apply the following rule of thumb: if a
recommendation was rated for each or most of the cri-
teria as ‘yes’, the recommendation was rated as a ‘strong
recommendation’. If only one or a few judgements
strongly favoured a recommendation, it was classed
simply as a ‘recommendation’. The rationale for this
ﬂexible approach lies in the fact that the weight each of
these criteria bears on the ﬁnal classiﬁcation can vary
depending on the recommendation at hand and/or on
the extent to which a certain criterion speaks for or
against a recommendation. In summary, a judgement
based on integration of transparent assessments for
Box 1 Definition of a clinical trial
Clinical trial:
A clinical trial is any research study that prospectively assigns
human participants or groups of humans to one or more
health-related interventions to evaluate the effects on health out-
comes. Clinical trials may also be referred to as interventional
trials. Interventions include but are not restricted to drugs, cells
and other biological products, surgical procedures, radiological
procedures, devices, behavioural treatments, process-of-care
changes, preventive care, etc. This definition includes phase I–IV
trials.39
Figure 1 Example of framework worksheet used for discussion of recommendations.
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these criteria seemed more appropriate than following a
rigid and inﬂexible rule.20
The outcomes of all small group deliberations were
then discussed in the open plenary sessions until a con-
sensus on all recommendations was reached. The OPEN
Consortium and the other meeting participants then
endorsed the full set of recommendations.
Following our workshop, the list of endorsed recom-
mendations was circulated and reﬁned by members of
the OPEN Consortium. As a last step, the ﬁnal recom-
mendations document was sent to all participants of our
recommendations workshop for ﬁnal technical revisions
and approval.
RESULTS
In this report, we ﬁrst present four general overarching
recommendations—aimed at major stakeholders in the
knowledge generation and translation process—followed
by the main results from the OPEN project, that is, 47
targeted recommendations addressing 11 key stake-
holder groups.
General recommendations
Each general recommendation is followed by an explan-
ation of the rationale and reasons why it was rated as
‘strong’ or not based on our decision table (see online
supplementary ﬁle 1 for detailed decision tables).
1. All stakeholders should raise awareness about dissem-
ination bias and measures to reduce it (strong
recommendation).
Awareness of the problem of dissemination bias is a
prerequisite for change. However, some of the responses
to our surveys indicated that many people still deem this
problem not relevant.17 It needs to be emphasised
among all stakeholder groups that dissemination bias
may have serious consequences on the health of people
and the trust in research.
We decided to make this a strong recommendation
because we think that the beneﬁts of this recommenda-
tion clearly outweigh its potential drawbacks and that
only limited resources are necessary for its implementa-
tion (as has recently been shown by the AllTrials
campaign7). Potential drawbacks of this strong recom-
mendation are that it might not be very effective in the
short term and that it might face some opposition. But
the Consortium deems the recommendation to be
highly effective in the long run, and recognises that any
opposition is likely to be due to passivity on the part of
the key stakeholder groups and the limited resources
available for actively engaging in raising awareness, and
emphasising its relevance. Another important aspect
that was identiﬁed is the need to extend awareness-
raising activities to patients and their representatives. All
patients participating in clinical trials should be made
aware of the fact that their participation only contributes
to scientiﬁc progress if the results are published, and
that this is often not the case.
2. All stakeholders should disseminate and facilitate the
implementation of targeted OPEN recommendations
as outlined in table 1 (strong recommendation).
In order for our recommendations to have an impact,
they need to be disseminated to as many representatives
of the key stakeholder groups as possible. Another pre-
requisite to change is that the stakeholders make a col-
lective effort. The problem of dissemination bias needs
to be addressed through concerted activities that
include several or all stakeholders in order to prevent
responsibilities from being shifted from one stakeholder
to the other (our research showed that many groups
believe it to be ‘somebody else’s problem’).
This recommendation was rated a strong recommenda-
tion. Its drawbacks are the likelihood of some opposition,
and the need for substantial resources for comprehensive
dissemination and implementation. While the dissemin-
ation of the recommendations alone will not effectively
reduce dissemination bias, their full or even partial
implementation should help reduce dissemination bias.
In order to be fully effective, tailored dissemination and
implementation strategies will be necessary.
3. All stakeholders should promote trial registration and
posting of results, and support initiatives that facilitate
searches across multiple trial registries (strong
recommendation).
Clinical trial registers are important sources for identi-
fying completed and ongoing trials. Efforts to promote
prospective registration of trials are, therefore, crucial.
The usefulness of registers, however, depends on the
completeness and comprehensiveness of the included
information.21 Accordingly, adequate quality control
measures need to be implemented. It also became
evident that metasearching, the possibility of searching
across different registries through a single interface, is
key to their usefulness. This is highly relevant consider-
ing existing language barriers and a lack of awareness of
the existence of national registries among users, which
might result in relevant registers not being included in
their searches. A platform offering a metasearch for
trials across multiple registries would help in identifying
trials that would otherwise have been missed.
This recommendation was considered to have long-
term, rather than immediate, impact. Together with the
favourable balance of beneﬁts and drawbacks, the knowl-
edge of how limited resources could hinder good imple-
mentation led us to make this a strong recommendation.
As a result of the US FDA Amendments Act, Section 801,
passed in 2007, ClinicalTrials.gov has required (since
September 2008) the posting of results of aggregate data
from applicable trials by researchers within 12 months of
completion.22 Once more registries adopt this approach
and once platforms allowing metasearching are available,
clinical trial registers will become essential tools to
reduce dissemination bias.
4. All stakeholders should support activities to systematic-
ally, with rigorous methodology, synthesise informa-
tion from studies (strong recommendation).
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Table 1 Targeted recommendations by key stakeholder group
Number Recommendation
Funding agencies
1.1 Funding agencies should include a statement on dissemination bias and the requirement for the dissemination of
research results in all calls for proposals (strong recommendation)
1.2 Funding agencies should include the requirement for grantees to provide a dissemination plan for funded projects
in all calls for proposals (strong recommendation)
1.3 Funding agencies should include the requirement for grantees to explicitly declare that the results of funded
research will be disseminated, regardless of the nature of findings, in all funding contracts (strong
recommendation)
1.4 Funding agencies should implement measures to ensure that the evaluation process of funded projects does not
end with the project’s final report, but instead is followed up until all agreed data have been disseminated
(recommendation)
1.5 Funding agencies should consider providing incentives for researchers who disseminate their results, or,
alternatively, withhold a part of the funding until a project’s results are adequately disseminated (recommendation)
1.6 Funding agencies should create a publicly accessible database of all grants awarded and on how their results were
disseminated in order to keep an accurate record of funded projects and publication outcomes (recommendation)
Pharmaceutical and device companies
2.1 Pharmaceutical and medical device companies should make their policies concerning the dissemination of
methods and results of clinical trials publicly accessible (strong recommendation)
2.2 Pharmaceutical and devices companies should register all clinical trials in a public registry before the recruitment
of the first participant (strong recommendation)
2.3 Pharmaceutical and devices companies should make their trial protocols+amendments (as submitted to RECs)
available on the publication/dissemination of results (strong recommendation)
2.4 Pharmaceutical and devices companies should publish/disseminate complete summary results (aggregate data) of
all trials conducted and provide access to their CSRs (for clinical trials) on request (recommendation)
Research institutions
3.1 Research institutions should provide guidance and training about the implications of and possible measures for
avoiding dissemination bias (strong recommendation)
3.2 Research institutions should not accept any funding that includes clauses that prevent the dissemination of data
(strong recommendation)
3.3 Research institutions should mandate the dissemination of complete summary results of all clinical trials (strong
recommendation)
Researchers I: systematic reviewers
4.1 Researchers conducting SRs, MAs and NMAs should follow the best practices25 38 for performing SRs (especially
those practices concerning the search for trials and the assessment of the impact of dissemination bias26) (strong
recommendation)
4.2 Systematic reviewers should make SR protocols and the results of SRs informing clinical care publicly available
(strong recommendation)
Researchers II: trialists
5.1 Trialists should register every trial they plan to conduct before the recruitment of the first participant (strong
recommendation)
5.2 Trialists should disseminate complete summary results (as soon as possible, but no later than 12 months) from all
clinical trials they conduct, that is, through journal publications and results/posting of results in registers (strong
recommendation)
5.3 Trialists should make trial protocols publicly available both within the register where the trial is registered and as
appendix/supporting material with the journal publication (strong recommendation)
RECs
6.1 RECs should require the registration of all clinical trials before the recruitment of the first participant (strong
recommendation)
6.2 RECs should require that applicants commit to making complete summary results publicly available
(recommendation)
6.3 RECs should encourage applicants to share anonymised individual patient-level data on request (strong
recommendation)
6.4 RECs should require that applicants provide annual reports describing the dissemination of their study results
(strong recommendation)
Trial registries
7.1 Trial registries should enable the reporting of aggregate summary results (strong recommendation)
7.2 Trial registries should enable and encourage the registration of observational human studies (recommendation)
Continued
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Table 1 Continued
Number Recommendation
7.3 Trial registries outside English-speaking countries should facilitate the registration process for
non-English-speaking trialists (strong recommendation)
7.4 Initiatives should be developed that enable non-English speakers to use the information contained in trial registers
(recommendation)
7.5 Trial registries should enable and encourage the inclusion of links to publications and other permanent data
sources (eg, PubMed, other bibliographical databases, data repositories) in trial registry entries (strong
recommendation)
7.6 All trial registries should comply with the WHO International Standards for Clinical Trials Registries (strong
recommendation)
Journal editors/publishers
8.1 Journal editors and publishers should remove all barriers to publishing negative or inconclusive studies and
consider studies for publication regardless of the direction of their findings or their sources of funding (strong
recommendation)
8.2 All journals should make trial registration a requirement for publication (strong recommendation)
8.3 Journals should check all submitted manuscripts against study protocols and/or trial registry entries to detect
selective reporting (strong recommendation)
8.4 Journal editors should publish editorials and commentaries about the problem of dissemination bias and the
benefits of trial registration (recommendation)
8.5 Journals should check for redundant publication of results by using text-matching software and asking peer
reviewers about papers reporting the same findings (strong recommendation)
Regulatory agencies
9.1 Regulation of pharmaceutical products should be extended to cover other therapeutic and diagnostic agents, such
as medical devices and biologicals (strong recommendation)
9.2 Responsible authorities (such as the EMA for drugs) should mandate that all clinical trials in humans falling under
their remit are registered in an EU database that is publicly accessible (strong recommendation)
9.3 Responsible authorities (such as EMA for drugs) should mandate that, on a trial’s registration in an EU database,
the full protocol approved by the REC, including the potential protocol amendments, is submitted and made
publicly available as a searchable document (strong recommendation)
9.4 Responsible authorities (such as EMA for drugs) should mandate that the full report, including all results (eg, CSR)
of a trial, is made available in the same registry that the trial was registered in, in a timely fashion (ie,1 year after
trial completion or inactivity) for all trials registered in the EU database (strong recommendation)
9.5 Responsible authorities (such as EMA for drugs) should ensure that trial sponsors failing to comply with such
result submission requirements are sanctioned (strong recommendation)
Benefit assessment institutions
10.1 Benefit assessment institutions should make their methods and processes of benefit assessment publicly
available, in order to achieve better transparency and understanding (strong recommendation)
10.2 Benefit assessment institutions should aim for a higher degree of collaboration between institutions to facilitate the
detection of further (unpublished) data and to foster data sharing (strong recommendation)
10.3 Benefit assessment institutions should use the full evidence base available for an intervention for their
assessments (strong recommendation)
10.4 Benefit assessment institutions should specify their course of action if they find that the evidence base for an
assessment is deemed incomplete (eg, no adequate proof of benefit based on incomplete data set) (strong
recommendation)
10.5 Benefit assessment institutions should request from legislators the following items which will allow the
consideration of all study results (disclosure of full protocols and full CSRs):
A. A legal obligation for manufacturers to submit all requested evidence
B. Public access to EMA databases
C. Public access to protocols and full study reports
(strong recommendation)
Legislators
11.1 Legislators should make prospective registration of clinical trials in humans mandatory (strong recommendation)
11.2 Legislators should ensure that all data related to the health of patients and the public are NOT commercially
confidential/proprietary information (strong recommendation)
11.3 Legislators should institute a legal obligation for manufacturers to submit all data and other required information for
the formal decision-making process (strong recommendation)
11.4 Legislators should ensure that the raw data (anonymised individual patient data) are made publicly available for all
clinical trials (registered in the EU database) (strong recommendation)
CSR, clinical study report; EMA, European Medicines Agency; EU, European Union; MA, meta-analysis; NMA, network meta-analysis; REC,
research ethics committee; SR, systematic review.
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The work of identifying all studies that address a particu-
lar question undertaken by authors of systematic reviews
helps detect dissemination bias. These efforts include sys-
tematic literature searches across electronic databases, the
search of trial registries23 and grey literature as well as con-
tacting experts in the ﬁeld. Also helpful in detecting dis-
semination bias are, for example, the exploration of
selective reporting of outcomes as part of the detailed risk
of bias evaluation within systematic reviews,24 and the
graphical (eg, funnel plots) and statistical assessment of
potentially selective publication of whole studies (eg,
Egger’s test).25 26 Finally, users of systematic reviews will be
made aware of the potential impact of dissemination bias
on the interpretation of the ﬁndings (if these are clearly
described by the review authors).
It was noted during the discussion that the availability
of systematic reviews in languages other than English
needs to be increased to achieve wider dissemination
and use of these crucial resources for evidence-based
decision-making.27 Broad acceptance and use of system-
atic reviews will also help to increase awareness about
the problem of dissemination bias, as suggested in rec-
ommendation #1.
Specific recommendations targeted at key stakeholder
groups
The 47 speciﬁc recommendations targeted at funding
agencies, pharmaceutical and device industry, research
institutions, researchers (systematic reviewers and trial-
ists), research ethics committees, trial registries, journal
editors and publishers, regulatory agencies, beneﬁt
assessment institutions and legislators are presented in
table 1.
While they focus on broader concepts such as trans-
parency (trial registration, access to study protocols and
results data), education and training, the tackling of lan-
guage barriers, and regulatory and legislative activities to
counteract selective dissemination, they do provide clear
guidance on activities that could and should be under-
taken by the respective key stakeholder groups. It is
obvious that some of these recommendations are also
relevant for other stakeholder groups; however, we
decided to list them primarily among those key groups
where the largest impact can be expected. More detailed
rationales as well as related assessments based on our
decision tables for these targeted recommendations will
be discussed more extensively in forthcoming articles
and will be made available through the OPEN website
(http://www.open-project.eu).
DISCUSSION
The OPEN project included a broad range of key stake-
holders across all relevant areas of the knowledge gener-
ation and knowledge translation process. The research
that was undertaken within the separate work packages
not only shed light on current measures in place to limit
dissemination bias, but also gathered the views of key
stakeholders on the possible barriers to transparency in
medical research. Thus, based on the evidence collated
throughout the ﬁrst phase of OPEN, a draft set of pre-
liminary recommendations for each stakeholder group
was developed. These were then discussed with the
OPEN Consortium, the advisory board of OPEN and
with selected external key stakeholders to capture the
different perspectives.
Instead of solely describing aspects of the general
problem of dissemination bias, in addition to the
general recommendations, we developed several tar-
geted and concrete recommendations that speciﬁcally
address each key stakeholder group and thus, as a
whole, offer a holistic approach to address the problem.
Further, due to the discussions held on topics such as
possible opposition, resources required and implement-
ability, we were able to go beyond generic recommenda-
tions. The detailed rationales and explanations for these
recommendations will be made available soon in separ-
ate articles and through the OPEN website (http://www.
open-project.eu). By means of this dissemination strat-
egy, we hope to expedite the widespread dissemination
and uptake of OPEN recommendations, by the relevant
key groups and institutions, and to thus initiate the
implementation of more adequate mechanisms to
reduce and prevent dissemination bias in the long run.
Although we developed separate sets of recommenda-
tions for industry and public funding agencies, it is
important to highlight that we agreed that the same
ethical considerations apply to all research funders.
After all, the interests of patients and the public in
general should always override commercial or other
interests.28 During workshop discussions it was noted
that the tendency of for-proﬁt companies and also (to
some extent) other stakeholder groups such as medical
licensing bodies, research institutions or policymakers
and legislators, to place the protection of commercial
interest over the public interest in access to data from
clinical trials, does not seem to be proportional.29 30
Despite the fact that companies are investing large sums
of money to develop new treatments, the group agreed
that intellectual and commercial property rights are
overall less important than basic human rights with
regard to information and health.
As already raised, it is obvious that some of our recom-
mendations are relevant for more than one stakeholder
group. The recommendations for beneﬁt assessment
institutions, for example, are also applicable for regula-
tors; however, they are speciﬁcally for beneﬁt assessment
agencies since work conducted within OPEN revealed
that cooperation between agencies, and the transpar-
ency of methodology used, could particularly be
improved within this key group. Similarly, recommenda-
tions with respect to data sharing, for example, for
research ethics committees and legislators, are again
also relevant for other key groups. It needs to be kept in
mind, though, that data sharing was not the focus of the
OPEN project.
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We hope that the results of our project will comple-
ment and support ongoing and future activities aiming
for more transparency in clinical trial results dissemin-
ation. As outlined in the OPEN paper on our concep-
tual approach to the problem of selective dissemination
and resulting dissemination bias (Bassler et al, submitted
for publication), the OPEN project is unique in that it
aimed to determine which stakeholder groups should be
held responsible, and for identifying what they can do to
reduce and eliminate this multifaceted and multidimen-
sional problem. In addition, all stakeholders who are
willing to address the problem can now be provided with
clear and concrete recommendations for action.
While the OPEN project aims mainly at supporting
changes that will result in greater transparency in the
knowledge generation and knowledge translation process
in the future, it is clear that transparency and free access
to data also need to be established for past trials of
current treatments. As recently raised by Doshi et al8 as
well as by the AllTrials campaign (http://www.alltrials.
net), the complete and unbiased reporting of ﬁndings
from past trials is equally important for securing access to
the full evidence. The broader issue of waste in research,
ﬁrst introduced by Chalmers and Glasziou,31 has recently
been explored in a series of articles including—among
others—waste due to inaccessible research,32 and waste
due to incomplete or unusable research reports.33
The recommendations from the OPEN project coin-
cide with a number of important decisions at the
European Medicines Agency (EMA) and the European
Parliament, namely, the ﬁnalisation and implementation
of the EMA’s data sharing policy. EMA and the European
Parliament, which approved the new European clinical
trials regulation on 2 April 2014, have received praise for
their leadership on facilitating access to clinical study
reports.34 However, the recently released draft terms for
use of these reports included several important restric-
tions, such as strict conﬁdentiality, access to registered
users and on-screen viewing only.35 36 Certainly, this
would impede the widespread and most effective use of
these important data sources. Criticism was voiced by aca-
demia, to which EMA responded with a press release
announcing more user-friendly amendments.37 As of
now, it is unclear what the ﬁnal policy will look like.
We hope that the ﬁndings from the OPEN project will
contribute to these decisions and implementation pro-
cesses, emphasising once more the needs of academia
and the public for unrestricted access to an unbiased
body of evidence of complete results of all clinical trials.
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